Compare Neurocrine Biosciences Inc (NBIX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Tenet Healthcare Corporation — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while Tenet Healthcare Corporation trades at $260.39 (market cap $20.93B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | THC | |
|---|---|---|
Market Cap | $16.76B | $20.93B |
Sector | Health | Health |
52-Week High | $185.50 | $262.63 |
52-Week Low | $123.10 | $161.37 |
Enterprise Value | $16.78B | $32.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Tenet Healthcare (THC) trades at $262.13, up 2.14% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $6.12 versus $4.26 expected, while valuation metrics remain attractive with P/E of 10.05 and EV/EBITDA of 5.74. Recent institutional buying and positive earnings revisions support the upward trend.
Outlook remains positive with consensus price target of $281.44 offering 7.4% upside potential. Key risks include healthcare policy headwinds and competitive pressures, but strong ambulatory growth and expense management provide fundamental support. The stock presents a compelling value-growth combination for investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
